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Proinflammatory cytokines, such as tumor necrosis factor-or, interleukin-6, 
and interleukin-8, and antiinflammatory c tokines, such as interleukin-10, 
may play an important role in patient responses to cardiopulmonary b pass. 
We sought o define whether the myocardium and the lungs serve as important 
sources of these cytokines under conditions of cardiopulmonary b pass. Ten 
patients (age 64 _ 3 years, mean -+ standard error of the mean) undergoing 
elective coronary artery bypass grafting were monitored with an arterial 
catheter, a coronary sinus catheter, and a pulmonary artery catheter. Plasma 
levels of tumor necrosis factor-a, intedeukin-6, interleukin-8, and interleu- 
kin-10 were measured simultaneously in peripheral arterial blood, coronary 
sinus blood, and mixed venous blood before heparin administration, I minute 
before aortic crossclamping, 5 minutes after aortic declamping, and at 0.5, 1, 
1.5 and 2 hours after aortic dedamping. The durations of cardiopulmonary 
bypass and aortic crossclamping were 114 -+ 9 and 64 -+ 5 minutes, respec- 
tively. Levels of tumor necrosis factor-t~ and interleukin-6 were significantly 
higher in coronary sinus blood than in arterial blood after aortic declamping. 
Tumor necrosis factor-t~ and interleukin-6 levels were also higher in mixed 
venous blood than in arterial blood within 1 hour after declamping. There were 
no significant differences among the three sampling sites with respect to 
intedeukin-8 and interleukin-10 levels. In one patient who had postoperative 
myocardial infarction, however, interleukin-8 levels were three times as high as 
in coronary sinus blood than in arterial blood. These data indicate that the 
myocardium is a major source of tumor necrosis factor-oz and interleukin-6 in 
patients undergoing cardiopulmonary b pass. The lungs may consume rather 
than release proinflammatory c tokines in the early phase of reperfusion. The 
source under these conditions of the antiinflammatory c tokine interleukin-10 
remains to be determined. (J Thorac Cardiovasc Surg 1996;112:806-11) 
H eart operations with cardiopulmonary bypass (CPB) are associated with a transient inflamma- 
tory response invoMng release of proinflammatory 
cytokines, 1-~° such as tumor necrosis factor-a 
(TNF_o0,1, 7, 8 interleukin-1 (IL-1), 2 interleukin-6 
(IL_6),3, 4, 7-9 and interleukin-8 (IL-8), s-l° and release 
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of the antiinflammatory c tokine interleukin-10 (IL- 
10).s, 10 The degree of release of the proinflammatory 
cytokines is directly related to the duration of isch- 
emia.7, 8
As yet, the source of these cytokines during and 
after CPB has not been defined. The myocardium is
the first tissue to be considered for this role. The 
myocardium is capable of synthesizing biologically 
active TNF-a  after endotoxin stimulation, n Endo- 
toxin release 1' 12 and complement component C5a 
production during CPB 13 may play an important 
role in inducing TNF-a.  IL-8 is released during 
reperfusion of the ischemic myocardium. 14 In pa- 
tients with acute myocardial infarction, the myocar- 
dium may release IL-6 and IL-8 after recanalization 
by balloon angioplasty, is Other organs may also 
contribute to the release of cytokines after ischemia 
and reperfusion, however; in particular, the lungs 
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and the liver are potential sources of IL-6, IL-8, and 
IL_10.16, 17 Accordingly, the aim of this study was to 
determine whether the heart or the lung is the major 
source organ of TNF-o~, IL-6, IL-8, and IL-10 in 
patients undergoing CPB. 
Patients and methods 
Eleven consecutive patients undergoing CPB for elec- 
tive coronary artery bypass grafting (CABG) were pro- 
spectively entered into this study, which was approved by 
the local ethical committee. All patients provided written, 
informed consent. Patients were undergoing reinterven- 
tion, had dysfunction of other organs (kidneys, liver, 
lungs), or were treated with corticosteroids before opera- 
tion were not included. One patient in whom the coronary 
sinus catheter was dislocated uring operation was also 
excluded from the study. The clinical data of the 10 
patients studied are shown in Table I. 
After induction of anesthesia,  Swan-Ganz thermodi- 
lution catheter (model 131H-7F; Baxter Healthcare 
Corp., Edwards Div., Irvine, Calif.) and a coronary sinus 
catheter (Pepine 2G, end hole; Webster Labs, Inc., Bald- 
win Park, Calif.) were inserted by the same anesthetist, 
with fluoroscopic guidance in each case. Coronary sinus 
cannulation was confirmed by contrast dye injection and 
oximetric testing of sampled coronary sinus blood. Although 
no complications were associated with coronary sinus can- 
nulation, the coronary sinus catheter was withdrawn 2hours 
after declamping to minimize any potential risk. 
No corticosteroids were administered before or during 
operation. Similar balanced anesthetic regimens including 
sufentanil and midazolam were used in all cases. Paralysis 
was achieved with pancuronium. Cefamandol (Mandol) 
was given intravenously for 48 hours starting from the 
induction of anesthesia s antimicrobial prophylaxis. All 
patients received aprotinin (Trasylol) intravenously at a 
dose of 280 mg within 30 minutes of the beginning of the 
operation and also received 280 mg at the beginning of 
CPB and 70 mg/hour during CPB, infused intravenously 
by pump. Anticoagulation was achieved with a loading 
dose of heparin of 3 mg/kg and further infusions as 
necessary to maintain n activated clotting time longer 
than 480 seconds during CPB. After discontinuation of 
CPB, heparin was neutralized with protamine sulfate at a 
dose equal to two thirds of the total dose of heparin. 
The extracorporeal circuit consisted of a roller pump 
(Stockert Instrumente Gmbh, Munich, Germany) and a 
membrane oxygenator (Optima, COBE Cardiovascular, 
Inc., Arvada, Colo.). Pump flow was maintained at 2.4 
L -m -2- rain 1. A cold crystalloid cardioplegic solution 
containing a lactated Ringer's solution with potassium 
chloride, magnesium chloride, and sodium bicarbonate, 
supplemented by topical slush hypothermia, was used for 
cardiac preservation. After each distal anastomosis, 80 to 
100 ml additional cold cardioplegic solution was delivered 
through the vein graft. Patients were cooled to around 
30 ° C. Rewarming began during the final distal anastomo- 
sis. The proximal anastomoses were completed with the 
aid of a tangential clamp after removal of the crossclamp. 
Blood samples were drawn simultaneously from an 
artery (peripheral arterial catheter or the arterial ine of 
Table I. Clinical data 
No.  o f  pat ients  10 
Sex (male/female) 8/2 
Age (years) 
Mean 64 + 3* 
Range 53-74 
Body surface area (m 2) 1.87 _+ 0.09* 
CPB time (min) 
Mean 114 +_ 9* 
Range 67-169 
Crossclamp time (min) 
Mean 64 _+ 5* 
Range 36 - 87 
No. of grafts 3.4 _+ 0.2* 
*Mean + standard error of the mean. 
the pump circuit), the coronary sinus, and the distal 
pulmonary artery portion of the Swan-Ganz catheter at 
the following time points: (1) before heparin administra- 
tion; (2) 1 minute before aortic crossclamping; and (3) 5 
minutes, (4) 30 minutes, (5) 1 hour, (6) 90 minutes, and 
(7) 2 hours after aortic declamping. All samples were 
anticoagulated with ethylenediaminetetraacetic acid,im- 
mediately cooled to 4 ° C, and centrifuged within 30 min- 
utes (3000g for 10 minutes at 4 ° C). Plasma was trans- 
ferred to a sterile polypropylene t st tube and stored at 
-20 ° C until assay. 
TNF-cg IL-6, IL-8, and IL-10 levels in the plasma were 
determined by means of commercially available nzyme- 
linked immunosorbent assays (Medgenix Diagnostics, 
Fleurus, Belgium). No adjustment was made for hemodi- 
lution. The sensitivity was 20 pg/ml for TNF-cg 15 pg/ml 
for IL-6, 7.8 pg/ml for IL-8, and 14 pg/ml for IL-10. 
Data are presented as mean +_ standard error of the 
mean. Because comparisons were made between paired 
samples, with each patient serving as his or her own 
control, and the data were not normally distributed, a
Wilcoxon signed-rank test (StatView software Brain- 
power Inc., Calabasas, Calif.) was used to compare cyto- 
kine levels among the three sampling sites at each sam- 
pling time point. Statistical significance was attributed top 
values lower than 0.05. 
Results 
The clinical data are summarized in Table I. Each 
patient received at least one internal mammary artery 
graft on the left anterior descending coronary artery. 
All patients urvived the hospital stay, and no patients 
required reexploration for bleeding after operation. 
Nine of 10 patients were discharged from the 
intensive care unit on the first postoperative day. 
The other patient, a 54-year-old man who received 
three grafts, had the longest duration of CPB (169 
minutes) and aortic crossclamping (87 minutes); he 
required a 10 to 20 mg.  kg -1 .  min 1 dobutamine 
infusion for weaning from CPB. In the postoperative 
period, the patient showed a significant release of 
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Fig. 1. Plasma levels of TNF-c~ (A), IL-8 (B), IL-6 (C), and IL-10 (D) in peripheral rtery (A), pulmonary 
artery (PA), and coronary sinus (CS) in one patient undergoing CABG who had postoperative myocardial 
infarction. BH, Before heparin administration; CC, 1 minute before aortic crossclamping; DC, 5 minutes 
after aortic declamping; 0.Sh, lh, 1.5h, 2h, time points after declamping. 
creatine kinase isoenzyme MB (69 IU/L vs 27 _+ 3 
IU/L in the other nine patients), associated with 
electrocardiographic evidence of myocardial infarc- 
tion (new-onset Q waves on leads V1 to V3). The 
levels of the four cytokines measured were 4 to 10 
times as high in this patient as in the other nine 
patients (Figs. 1 and 2). IL-8 levels in this patient, 
like TNF-o~ and IL-6 levels, were much higher in 
coronary sinus blood than in arterial blood after 
aortic declamping (Fig. 1). 
Cytokine levels in the other nine patients are 
presented in Fig. 2. TNF-~ values increased 5 
minutes after aortic declamping and were signifi- 
cantly higher in coronary sinus blood than in 
arterial blood throughout the study period. IL-6 
levels increased slightly later after declamping but 
were also greater in coronary sinus blood than in 
arterial blood. Levels of TNF-o~ and IL-6 were 
also significantly higher in mixed venous blood 
than in arterial blood within 1 hour after declamp- 
ing. There were no differences in IL-8 levels 
among the three sampling sites. IL-10 values were 
similar among the three sampling sites in all 
patients (Figs. 1 and 2). 
Discuss ion  
Numerous clinical studies have shown significant 
elevation of blood cytokine levels during and after 
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Fig. 2. Plasma levels of TNF-a (A), IL-8 (B), IL-6 (C), and IL-10 (D) in peripheral rtery (A), pulmonary 
artery (PA), and coronary sinus (CS) in nine patients undergoing uncomplicated CABG. Data are mean 2 
standard error of mean (error bars). Asterisk indicates p < 0.05; dagger indicates p < 0.01 versus arterial. 
BH, Before heparin administration; CC, 1 minute before aortic crossclamping; DC, 5 minutes after aortic 
declamping; 0.5h, lh, 1.5h, 2h, time points after declamping. 
CPB. 1-1° Such a phenomenon can be induced by 
several factors, including ischemia-repeffusion, 7'8 
complement activation, and release of endotoxin. 1 
TNF-a may play an important role in the inflamma- 
tory response after CPB, not only because it may 
directly induce some symptoms, uch as fever, tachy- 
cardia, and hypotension, is but also because it may 
trigger the release of other important cytokines, 
such as IL-819 and IL-10. 2° IL-6 is a good marker of 
injury severity, even though it does not have toxic 
effects itself. 21' 22 IL-8 is a crucial mediator in isch- 
emia-reperfusion injury in patients undergoing 
CPB. 5-1° IL-8 release is induced only after reperfu- 
sion of the ischemic myocardium in animals 14' 23 as 
well as in human beings) 5
The release of proinftammatory cytokines may be 
important because such a release seems to be impli- 
cated in the development of postoperative compli- 
cations.6, 7 9 A better understanding of these cyto- 
kine responses may lead to new therapeutic 
implications. Administration of anti-IL8 antibodies 
prevents lung ischemia-reperfusion injury in rab- 
bits. 24 Anti-TNF antiserum may reduce pulmonary 
and hepatic injury caused by hepatic ischemia-reper- 
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fusion. 25 Such anticytokine strategies may also be 
useful in cardiac operations. Removal of TNF-a and 
IL-6 by hemofiltration has been shown to have 
beneficial effects in children undergoing CPB. 26 
Administration of steroids before CPB not only 
reduces ignificantly the release of proinflammatory 
cytokinesl0, 27 but also increases the release of IL- 
l0. l° In heart and heart-lung transplantation, ad- 
ministration ofsteroids before the procedure, rather 
than at the end of CPB as usual, significantly 
reduces the production of TNF-a and IL-8 but 
greatly increases the release of IL-10. 2s 
For better insight into the pathophysiology in-
volved, it is important to identify the primary source 
of these cytokines. There are, however, no reported 
data indicating the source organ of these cytokines 
in patients undergoing CPB. To study the myocar- 
dial contribution to the release of cytokines, we 
inserted a catheter into the coronary sinuses of 
patients undergoing CABG. We found that levels of 
TNF-a and IL-6 were significantly higher in coro- 
nary sinus blood than in arterial blood, indicating 
that the myocardium is a major source of these two 
proinflammatory c tokines in patients undergoing 
CPB. Furthermore, IL-8 levels in one patient who 
had postoperative myocardial infarction were three 
times as high in coronary sinus blood as in arterial 
blood, suggesting that the myocardium ay release 
IL-8 during more severe injury. Because the data 
analysis involved multiple comparisons, the degree 
of statistical significance may have been overstated. 
Nevertheless, the positive findings were consistent 
enough to indicate that the observed ifferences 
were real. 
Our data do not exclude significant cytokine 
release by other organs. In fact, other organs also 
have inadequate blood supply during CPB and could 
similarly be important sources of mediators. Fur- 
thermore, the release of endotoxin frequently ob- 
served during CPB, as well as complement activa- 
tion, may trigger the release of cytokines. In 
particular, the lungs and the liver may play espe- 
cially important roles because these organs are able 
to produce cytokines, including TNF-a, IL-6, and 
IL-8, in response to different forms of injury. 16' 17, 29 
The lungs can release TNF-a during ischemia nd 
reperfusion under certain circumstances. 29 The 
lungs and liver may contribute to IL-6 production i  
thermal injury. 17 lschemia-reperfusion of the liver 
also induces a massive release of IL-8.16 Cytokine 
release by the lungs, however, would have resulted 
in higher cytokine levels in arterial blood than in 
mixed venous blood, and this was not the case in our 
study. The lungs thus do not contribute significantly 
to the production of TNF-a, IL-6, and IL-8 during 
and after CPB, at least when the duration of isch- 
emia is relatively short, as it is in routine CABG 
procedures. In fact, TNF-a and IL-6 levels were 
significantly higher in mixed venous blood than in 
arterial blood shortly after reperfusion, indicating 
that the lungs may actually consume these proin- 
flammatory cytokines. 
Our findings also support some previous observa- 
tions. For example, Hennein and colleagues 7 
showed that the duration of aortic crossclamping 
was the only independent predictor of postoperative 
TNF-a and IL-6 levels in 22 patients undergoing 
uncomplicated CABG. We s recently demonstrated 
that TNF-a, IL-6, and IL-8 levels were much higher 
in patients undergoing heart transplantation, in 
whom the duration of myocardial ischemia was 
much longer, than in those undergoing CABG. 
Furthermore, the release of IL-6 and IL-8 corre- 
lated significantly with the duration of ischemia. 8 
Our current data dearly document that TNF-a and 
IL-6 were released mainly from ischemic myocar- 
dium after reperfusion. The myocardium ay also 
be, however, an important source of IL-8 during 
reperfusion after longer ischemic periods &3o or 
acute myocardial infarction. 15 It may be noteworthy 
that no adjustment was made for hemodilution i
our study. If we had done so, the elevation of 
cytokine levels would have been even greater. 
The antiinflammatory cytokine IL-10 is also re- 
leased during CPB, 8' 10 but its tissue source under 
such conditions still needs to be determined. In this 
study, IL-10 levels were similar among the three 
sampling sites, indicating that neither the heart nor 
the lungs serve as the main source of IL-10 produc- 
tion. The liver may be an important source of 
IL-10.16 Further investigation is required to evaluate 
this possible mechanism of IL-10 production during 
CPB. 
In summary, this study demonstrates that the 
heart, not the lungs, is a major source of the 
proinflammatory c tokines TNF-a and IL-6 after 
reperfusion of ischemic myocardium in patients 
undergoing CPB. The lungs may even consume 
these proinflammatory cytokines under such condi- 
tions. Neither the heart nor the lungs are the main 
source of the antiinflammatory cytokine IL-10. 
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